Skip to content
Blerp – Lifestyle
Author:
Purecore Metals Inc.
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
August 18, 2026
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
August 6, 2026
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
July 15, 2026
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
June 2, 2026
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
May 22, 2026
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
May 15, 2026
Purecore Metals Inc. Announces Listing on the Canadian Securities Exchange Under the Symbol “PURE”
May 15, 2026
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
May 7, 2026